---
document_datetime: 2025-09-08 16:04:09
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eksunbi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: eksunbi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.9710455
conversion_datetime: 2025-12-28 03:22:15.654983
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 23/05/2025                          |                                             | SmPC and PL                      | To update section 4.5 and 5.2 of the SmPC in order |

Eksunbi Procedural steps taken and scientific information after the authorisation* *Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) . Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

## EMA/VR/0000267789

to add drug-drug interaction information based on results from study CNTO1275CRD100, and sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001. The change follows assessment of the same change to the reference product, Stelara.

Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD100, and sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001. The change follows assessment of the same change to the reference product, Stelara.   Furthermore, the MAH took the opportunity to add a warning for Polysorbate 80 to section 4.4 of the SmPC in line with the reference product and the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' Medicinal product no longer authorised